Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xbrane Biopharma AB's Total Assets for the quarter that ended in Jun. 2026 was kr642.61 Mil.
Warning Sign:
If a company builds assets at 21.6% a year, faster than its revenue growth rate of 17.3% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Xbrane Biopharma AB's average Total Assets Growth Rate was -0.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 5.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 21.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 27.70% per year.
During the past 13 years, Xbrane Biopharma AB's highest 3-Year average Total Assets Growth Rate was 564.60%. The lowest was 5.60%. And the median was 33.10%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Xbrane Biopharma AB's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Xbrane Biopharma AB Total Assets Related Terms
Xbrane Biopharma AB Total Assets Historical Data
* Premium members only.
The historical data trend for Xbrane Biopharma AB's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Xbrane Biopharma AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xbrane Biopharma AB (OSTO:XBRANE) has a Total Assets of kr642.61 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's Total Assets too high?
Xbrane Biopharma AB's current Total Assets is kr642.61 Mil. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Total Assets compare to VRTX and REGN?
Xbrane Biopharma AB's Total Assets of kr642.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current Total Assets is kr642.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (OSTO:XBRANE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr5.97, compared to a current price of kr9.18 — trading 53.8% above its estimated fair value. The current Total Assets is kr642.61 Mil. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Xbrane Biopharma AB (OSTO:XBRANE), the current Total Assets is kr642.61 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xbrane Biopharma AB (OSTO:XBRANE) Overvalued in 2026?
Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued.
The current stock price of kr9.18 is trading 53.8% above its estimated GF Value™ of kr5.97.
GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:XBRANE:
Total Assets: kr642.61 Mil
GF Value™: kr5.97 vs. price of kr9.18 (53.8% above fair value)
No single metric tells the full story. See the OSTO:XBRANE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score
Get the complete analysis for OSTO:XBRANE
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:XBRANE has been successfully added to your 
